1887

n Cardiovascular Journal of South Africa - Dramatic new trial results settle controversy in chronic heart failure : drug trends in cardiology

Volume 14, Issue 3
  • ISSN : 1680-0745
USD

 

Abstract

Extracted from text ... Dramatic new trial results settle controversy in chronic heart failure The results of the COMET study, the first-ever head-to-head mortality comparison of two beta-blocking agents in patients with chronic heart failure (CHF) were recently announced by the COMET Steering Committee. They demonstrate that carvedilol (Dilatrend (r)), a comprehensive beta-blocking agent, saves significantly more lives than metoprolol, a conventional betablocker. Patients receiving carvedilol had a significant survival benefit as compared to patients on metoprolol. The Carvedilol or Metoprolol European Trial (COMET), sponsored by F. Hoffmann-La Roche, was designed to resolve the controversy as to whether comprehensive or selective beta blockade is ..

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/cardio/14/3/EJC23836
2003-05-01
2016-12-10

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error